1. Home
  2. Live Updates
  3. நோர்டிக் லிம்போமா குழு

நோர்டிக் லிம்போமா குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோர்டிக் லிம்போமா குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோர்டிக் லிம்போமா குழு Today - Breaking & Trending Today

CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma


Share this article
Share this article
ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB ( BioInvent ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy today announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin s Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time (5:30 p.m. CET).
The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin s Lymphoma for whom current treatment options are very limited. ....

United States , Martin Welschof , Mary Ann Chang , Jennifer Porcelli , Bioinvent International , Bioinvent International Ab , Pharmaceuticals China Co Ltd , Lund University , Nordic Lymphoma Group , Pharmaceuticals Inc , Key Opinion Leader , Mats Jerkeman , Clinical Oncology , Swedish Lymphoma Register , Greater China , Private Securities Litigation Reform Act , Ann Chang , Casi Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , மேரி ஆண்டு சாங் , ஜெனிபர் போர்செல்லி , மருந்துகள் சீனா இணை லிமிடெட் , லண்ட் பல்கலைக்கழகம் , நோர்டிக் லிம்போமா குழு , மருந்துகள் இன்க் , விசை கருத்து தலைவர் ,

BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma


Share this article
Share this article
LUND, Sweden, Jan. 20, 2021 /PRNewswire/  BioInvent International AB ( BioInvent ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy today announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin s Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time (5:30 p.m. CET).
The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin s Lymphoma for whom current treatment options are very limited. Dr Jerkeman will also discuss his experience in treating these patients with BioInvent s anti-FcγRIIB antibody, BI-1206, a novel monoclonal antibody that specifically targets the antibody brakes to help overcome res ....

Lund University , Nordic Lymphoma Group , Bioinvent International Ab , Bioinvent International , Key Opinion Leader , Mats Jerkeman , Clinical Oncology , Swedish Lymphoma Register , லண்ட் பல்கலைக்கழகம் , நோர்டிக் லிம்போமா குழு , விசை கருத்து தலைவர் , மருத்துவ புற்றுநோயியல் , ஸ்விட்ச் லிம்போமா பதிவு ,